Invasive and Noninvasive Progression After Resection of Noninvasive Intraductal Papillary Mucinous Neoplasms.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
18
11
2020
medline:
1
9
2022
entrez:
17
11
2020
Statut:
ppublish
Résumé
To define frequencies, pattern of progression (invasive vs noninvasive), and risk factors of progression of resected noninvasive intraductal papillary mucinous neoplasms (IPMNs). There is a risk of progression in the remnant pancreas after resection of IPMNs. Four hundred forty-nine consecutive patients with resected IPMNs from 1995 to 2018 were included to the study. Patients with invasive carcinoma or with follow-up <6 months were excluded. Noninvasive progression was defined as a new IPMN, increased main pancreatic duct size, and increased size of an existing lesion (5 mm compared with preoperative imaging). Invasive progression was defined as development of invasive cancer in the remnant pancreas or metastatic disease. With a median follow-up of 48.9 months, progression was identified in 124 patients (27.6%); 108(24.1%) with noninvasive and 16(3.6%) with invasive progression. Median progression follow-up was longer for invasive progression (85.4 vs 55.9 months; P = 0.001). Five-and 10-year estimates for a cumulative incidence of invasive progression were 6.4% and 12.9% versus 26.9% and 41.5% for noninvasive progression. After risk adjustment, multifocality (HR 4.53, 95% CI 1.34-15.26; P = 0.02) and high-grade dysplasia (HGD) in the original resection (HR 3.60, 95% CI 1.13-11.48; P = 0.03) were associated with invasive progression. Progression to invasive carcinoma can occur years after the surgical resection of a noninvasive IPMN. HGD in the original resection is a risk factor for invasive progression but some cases of low-grade dysplasia also progressed to cancer. Patients with high-risk features such as HGD and multifocal cysts should be considered for more intensive surveillance and represent an important cohort for future trials such as anti-inflammatory or prophylactic immunotherapy.
Sections du résumé
OBJECTIVE
To define frequencies, pattern of progression (invasive vs noninvasive), and risk factors of progression of resected noninvasive intraductal papillary mucinous neoplasms (IPMNs).
BACKGROUND
There is a risk of progression in the remnant pancreas after resection of IPMNs.
METHODS
Four hundred forty-nine consecutive patients with resected IPMNs from 1995 to 2018 were included to the study. Patients with invasive carcinoma or with follow-up <6 months were excluded. Noninvasive progression was defined as a new IPMN, increased main pancreatic duct size, and increased size of an existing lesion (5 mm compared with preoperative imaging). Invasive progression was defined as development of invasive cancer in the remnant pancreas or metastatic disease.
RESULTS
With a median follow-up of 48.9 months, progression was identified in 124 patients (27.6%); 108(24.1%) with noninvasive and 16(3.6%) with invasive progression. Median progression follow-up was longer for invasive progression (85.4 vs 55.9 months; P = 0.001). Five-and 10-year estimates for a cumulative incidence of invasive progression were 6.4% and 12.9% versus 26.9% and 41.5% for noninvasive progression. After risk adjustment, multifocality (HR 4.53, 95% CI 1.34-15.26; P = 0.02) and high-grade dysplasia (HGD) in the original resection (HR 3.60, 95% CI 1.13-11.48; P = 0.03) were associated with invasive progression.
CONCLUSIONS
Progression to invasive carcinoma can occur years after the surgical resection of a noninvasive IPMN. HGD in the original resection is a risk factor for invasive progression but some cases of low-grade dysplasia also progressed to cancer. Patients with high-risk features such as HGD and multifocal cysts should be considered for more intensive surveillance and represent an important cohort for future trials such as anti-inflammatory or prophylactic immunotherapy.
Identifiants
pubmed: 33201121
pii: 00000658-202208000-00023
doi: 10.1097/SLA.0000000000004488
pmc: PMC9844542
mid: NIHMS1859474
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
370-377Subventions
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Ann Surg. 2015 Dec;262(6):1108-14
pubmed: 25793719
J Gastroenterol. 2020 Jan;55(1):86-99
pubmed: 31463655
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Ann Surg. 2012 Feb;255(2):326-33
pubmed: 22167000
Gut Liver. 2015 Sep 23;9(5):571-89
pubmed: 26343068
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):676-689
pubmed: 31527862
AJR Am J Roentgenol. 2013 Mar;200(3):563-9
pubmed: 23436845
Am J Surg Pathol. 2015 Dec;39(12):1730-41
pubmed: 26559377
Dig Surg. 2016;33(4):335-42
pubmed: 27215900
Gut. 2020 Jan;69(1):7-17
pubmed: 31672839
Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9
pubmed: 15166958
J Am Coll Surg. 2013 Apr;216(4):657-65; discussion 665-7
pubmed: 23395158
Ann Surg. 2014 Aug;260(2):356-63
pubmed: 24378847
Clin Gastroenterol Hepatol. 2012 May;10(5):555-8
pubmed: 22210438
J Am Coll Surg. 2007 May;204(5):987-93; discussion 993-5
pubmed: 17481526
Methods Mol Biol. 2019;1882:9-22
pubmed: 30378040
J Gastrointest Surg. 2013 Sep;17(9):1618-26
pubmed: 23813047
Clin Cancer Res. 2011 Mar 15;17(6):1502-8
pubmed: 21266527
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
J Hepatobiliary Pancreat Sci. 2015 Oct;22(10):757-65
pubmed: 26148131
Gastroenterology. 2019 Sep;157(3):720-730.e2
pubmed: 31175863
Pancreatology. 2016 May-Jun;16(3):309-17
pubmed: 26987800
HPB (Oxford). 2016 Mar;18(3):236-46
pubmed: 27017163
HPB (Oxford). 2013 Oct;15(10):814-21
pubmed: 23782351
HPB (Oxford). 2011 Nov;13(11):759-66
pubmed: 21999588
Ann Surg Oncol. 2018 Jun;25(6):1752-1759
pubmed: 29589164
Ann Surg. 2018 Aug;268(2):340-347
pubmed: 28700444
Am J Gastroenterol. 2019 Mar;114(3):524-529
pubmed: 30413822
J Gastrointest Surg. 2012 Feb;16(2):258-67; discussion 266
pubmed: 22089952